Clinical trial
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or…
NCT00118248 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118248 |
|---|---|
| Title | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer |
| Official title | A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Enrollment | 41 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2009 |
| Completion | Apr 1, 2012 |
| First posted | Jul 11, 2005 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: